Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Income (2019 - 2025)

Historic Equity Income for Neurocrine Biosciences (NBIX) over the last 6 years, with Q4 2025 value amounting to $2.7 million.

  • Neurocrine Biosciences' Equity Income rose 24210.53% to $2.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.0 million, marking a year-over-year increase of 8921.83%. This contributed to the annual value of -$4.0 million for FY2025, which is 8921.83% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Equity Income stood at $2.7 million, which was up 24210.53% from $30.6 million recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year Equity Income high stood at $37.3 million for Q2 2023, and its period low was -$40.1 million during Q3 2023.
  • In the last 4 years, Neurocrine Biosciences' Equity Income had a median value of -$600000.0 in 2021 and averaged -$1.4 million.
  • Within the past 5 years, the most significant YoY rise in Neurocrine Biosciences' Equity Income was 28106.51% (2025), while the steepest drop was 201250.0% (2025).
  • Neurocrine Biosciences' Equity Income (Quarter) stood at -$8.2 million in 2021, then soared by 453.66% to $29.0 million in 2023, then crashed by 106.55% to -$1.9 million in 2024, then soared by 242.11% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q4 2025, $30.6 million for Q3 2025, and -$6.7 million during Q2 2025.